RXDX 107

Drug Profile

RXDX 107

Alternative Names: CEP-40125; RXDX-107

Latest Information Update: 05 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Cephalon
  • Developer Ignyta
  • Class Antineoplastics; Benzimidazoles; Butyric acids; Nitrogen mustard compounds; Nitrosourea compounds; Small molecules
  • Mechanism of Action Apoptosis stimulants; DNA cross linking agents; DNA synthesis inhibitors; Mitosis modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Solid tumours

Most Recent Events

  • 23 Sep 2016 Ignyta terminates phase I trial in Solid tumours (Late-stage disease) in USA (NCT02548390)
  • 23 Feb 2016 Discontinued - Phase-I for Solid tumours (Late-stage disease) in USA (IV)
  • 06 Oct 2015 Ignyta has patent protection for composition of matter of RXDX 107 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top